213 related articles for article (PubMed ID: 32238166)
1. High-intensity interval training in allogeneic adoptive T-cell immunotherapy - a big HIT?
Heinemann NC; Tischer-Zimmermann S; Wittke TC; Eigendorf J; Kerling A; Framke T; Melk A; Heuft HG; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
J Transl Med; 2020 Apr; 18(1):148. PubMed ID: 32238166
[TBL] [Abstract][Full Text] [Related]
2. A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy.
Spielmann G; Bollard CM; Kunz H; Hanley PJ; Simpson RJ
Sci Rep; 2016 May; 6():25852. PubMed ID: 27181409
[TBL] [Abstract][Full Text] [Related]
3. The effects of β
Kunz HE; Agha NH; Hussain M; LaVoy EC; Smith KA; Mylabathula P; Diak D; Baker FL; O'Connor DP; Bond RA; Katsanis E; Bollard CM; Simpson RJ
Cell Stress Chaperones; 2020 Nov; 25(6):993-1012. PubMed ID: 32779001
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
5. Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults.
Galletta TJ; Lane A; Lutzko C; Leemhuis T; Cancelas JA; Khoury R; Wang YM; Hanley PJ; Keller MD; Bollard CM; Davies SM; Grimley MS; Rubinstein JD
Transplant Cell Ther; 2023 May; 29(5):305-310. PubMed ID: 36736781
[TBL] [Abstract][Full Text] [Related]
6. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
[TBL] [Abstract][Full Text] [Related]
7. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.
Tischer S; Priesner C; Heuft HG; Goudeva L; Mende W; Barthold M; Kloeß S; Arseniev L; Aleksandrova K; Maecker-Kolhoff B; Blasczyk R; Koehl U; Eiz-Vesper B
J Transl Med; 2014 Dec; 12():336. PubMed ID: 25510656
[TBL] [Abstract][Full Text] [Related]
8. Identification of the best-suited donor for generating virus-specific T cells.
Tasnády S; Karászi É; Szederjesi A; Bihari G; Juhász Z; Hardi A; Kriván G; Kállay K; Reményi P; Sinkó J; Mikala G; Réti M; Masszi T
Vox Sang; 2020 Jan; 115(1):18-26. PubMed ID: 31667887
[TBL] [Abstract][Full Text] [Related]
9. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B
J Clin Oncol; 2017 Nov; 35(31):3547-3557. PubMed ID: 28783452
[TBL] [Abstract][Full Text] [Related]
10. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
11. Transgenic CD8αβ co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells.
Bajwa G; Lanz I; Cardenas M; Brenner MK; Arber C
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148692
[TBL] [Abstract][Full Text] [Related]
12. Establishment and Operation of a Third-Party Virus-Specific T Cell Bank within an Allogeneic Stem Cell Transplant Program.
Withers B; Clancy L; Burgess J; Simms R; Brown R; Micklethwaite K; Blyth E; Gottlieb D
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2433-2442. PubMed ID: 30172015
[TBL] [Abstract][Full Text] [Related]
13. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.
Sun J; Huye LE; Lapteva N; Mamonkin M; Hiregange M; Ballard B; Dakhova O; Raghavan D; Durett AG; Perna SK; Omer B; Rollins LA; Leen AM; Vera JF; Dotti G; Gee AP; Brenner MK; Myers DG; Rooney CM
J Immunother Cancer; 2015; 3():5. PubMed ID: 25734008
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy.
Lugthart G; Albon SJ; Ricciardelli I; Kester MG; Meij P; Lankester AC; Amrolia PJ
J Immunother; 2012 Jan; 35(1):42-53. PubMed ID: 22130159
[TBL] [Abstract][Full Text] [Related]
15. A single exercise bout augments adenovirus-specific T-cell mobilization and function.
Kunz HE; Spielmann G; Agha NH; O'Connor DP; Bollard CM; Simpson RJ
Physiol Behav; 2018 Oct; 194():56-65. PubMed ID: 29723594
[TBL] [Abstract][Full Text] [Related]
16. Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant.
Rubinstein JD; Lutzko C; Leemhuis T; Zhu X; Pham G; Ray L; Thomas S; Dourson C; Wilhelm J; Lane A; Cancelas JA; Lipps D; Ferrell J; Hanley PJ; Keller MD; Bollard CM; Wang YM; Davies SM; Nelson AS; Grimley MS
Blood Adv; 2022 May; 6(9):2897-2907. PubMed ID: 35108727
[TBL] [Abstract][Full Text] [Related]
17. Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.
Qian C; Campidelli A; Wang Y; Cai H; Venard V; Jeulin H; Dalle JH; Pochon C; D'aveni M; Bruno B; Paillard C; Vigouroux S; Jubert C; Ceballos P; Marie-Cardine A; Galambrun C; Cholle C; Clerc Urmes I; Petitpain N; De Carvalho Bittencourt M; Decot V; Reppel L; Salmon A; Clement L; Bensoussan D
J Hematol Oncol; 2017 May; 10(1):102. PubMed ID: 28482908
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-specific T-lymphocyte efficacy in the presence of methylprednisolone: An in vitro study.
Campidelli A; Qian C; Laroye C; Decot V; Reppel L; D'aveni M; Bensoussan D
Cytotherapy; 2018 Apr; 20(4):524-531. PubMed ID: 29496461
[TBL] [Abstract][Full Text] [Related]
19. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
[TBL] [Abstract][Full Text] [Related]
20. Rapid Generation of TCR and CD8αβ Transgenic Virus Specific T Cells for Immunotherapy of Leukemia.
Bajwa G; Arber C
Front Immunol; 2022; 13():830021. PubMed ID: 35572604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]